NASDAQ:BNTC - BENITEC BIOPHAR/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.80 0.00 (0.00 %)
(As of 07/19/2018 03:31 PM ET)
Previous Close$2.80
Today's Range$2.80 - $2.80
52-Week Range$1.85 - $4.90
Volume1,700 shs
Average Volume259,948 shs
Market Capitalization$30.99 million
P/E RatioN/A
Dividend YieldN/A
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio8.63
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.36 million
Price / Sales3.69
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book1.77


EPS (Most Recent Fiscal Year)N/A
Net Income$-4,280,000.00
Net Margins-232.50%
Return on Equity-64.54%
Return on Assets-59.04%


Outstanding Shares11,030,000
Market Cap$30.99

The Truth About Cryptocurrencies

BENITEC BIOPHAR/S (NASDAQ:BNTC) Frequently Asked Questions

What is BENITEC BIOPHAR/S's stock symbol?

BENITEC BIOPHAR/S trades on the NASDAQ under the ticker symbol "BNTC."

How often does BENITEC BIOPHAR/S pay dividends? What is the dividend yield for BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S declared a ... dividend on Monday, May 28th. Shareholders of record on Monday, June 4th will be given a dividend of $0.0029 per share on Friday, June 8th. The ex-dividend date of this dividend is Friday, June 1st. View BENITEC BIOPHAR/S's Dividend History.

How were BENITEC BIOPHAR/S's earnings last quarter?

BENITEC BIOPHAR/S (NASDAQ:BNTC) posted its quarterly earnings data on Thursday, May, 31st. The biotechnology company reported ($0.22) EPS for the quarter. The biotechnology company had revenue of $0.96 million for the quarter. BENITEC BIOPHAR/S had a negative return on equity of 64.54% and a negative net margin of 232.50%. View BENITEC BIOPHAR/S's Earnings History.

When is BENITEC BIOPHAR/S's next earnings date?

BENITEC BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Tuesday, September, 4th 2018. View Earnings Estimates for BENITEC BIOPHAR/S.

What is the consensus analysts' recommendation for BENITEC BIOPHAR/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BENITEC BIOPHAR/S in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of BENITEC BIOPHAR/S's key competitors?

Who are BENITEC BIOPHAR/S's key executives?

BENITEC BIOPHAR/S's management team includes the folowing people:
  • Dr. Jerel A. Banks, Exec. Chairman
  • Ms. Megan Joan Boston, Exec. Director & Head of Operations Australia
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Annabel Murphy, Head of Investor Relations & Corp. Communications
  • Dr. Michael Graham BSc (Hons), Ph.D., Head of Discovery and Founding Scientist


(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Has BENITEC BIOPHAR/S been receiving favorable news coverage?

Press coverage about BNTC stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BENITEC BIOPHAR/S earned a media sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.67 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of BENITEC BIOPHAR/S?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BENITEC BIOPHAR/S's stock price today?

One share of BNTC stock can currently be purchased for approximately $2.80.

How big of a company is BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S has a market capitalization of $30.99 million and generates $8.36 million in revenue each year. BENITEC BIOPHAR/S employs 18 workers across the globe.

How can I contact BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S's mailing address is 99 Mount Street Suite 1201, Sydney C3, 2060. The biotechnology company can be reached via phone at 61-2-9555-6986 or via email at [email protected]

MarketBeat Community Rating for BENITEC BIOPHAR/S (NASDAQ BNTC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about BENITEC BIOPHAR/S and other stocks. Vote "Outperform" if you believe BNTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.